Acumen Pharma Says ALTITUDE-AD Missed Primary, Key Secondary Endpoints In Alzheimer's Study; Co. To Cease Clinical Development Of Sabirnetug, Preserve Cash And Explore Strategic Options

뉴스 본문을 불러오고 있어요.

Acumen Pharma Says ALTITUDE-AD Missed Primary, Key Secondary Endpoints In Alzheimer's Study; Co. To Cease Clinical Development Of Sabirnetug, Preserve Cash And Explore Strategic Options | 웨이프 WAPE

Acumen Pharma Says ALTITUDE-AD Missed Primary, Key Secondary Endpoints In Alzheimer's Study; Co. To Cease Clinical Development Of Sabirnetug, Preserve Cash And Explore Strategic Options

기사 요약

관련 종목

웨이프 AI가 분석했어요.

알츠하이머 임상 실패로 Sabirnetug 개발을 중단하고 전략적 옵션을 모색해요.

댓글 —